Exicure (XCUR) Competitors $3.74 -0.14 (-3.61%) As of 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XCUR vs. ANRO, SRZN, EXOZ, CNTB, IPA, STTK, KALA, ANIX, VIRI, and ORMPShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include Alto Neuroscience (ANRO), Surrozen (SRZN), eXoZymes (EXOZ), Connect Biopharma (CNTB), ImmunoPrecise Antibodies (IPA), Shattuck Labs (STTK), KALA BIO (KALA), Anixa Biosciences (ANIX), Virios Therapeutics (VIRI), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Its Competitors Alto Neuroscience Surrozen eXoZymes Connect Biopharma ImmunoPrecise Antibodies Shattuck Labs KALA BIO Anixa Biosciences Virios Therapeutics Oramed Pharmaceuticals Exicure (NASDAQ:XCUR) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends. Which has more risk & volatility, XCUR or ANRO? Exicure has a beta of 3.84, indicating that its share price is 284% more volatile than the S&P 500. Comparatively, Alto Neuroscience has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Does the media prefer XCUR or ANRO? In the previous week, Alto Neuroscience had 31 more articles in the media than Exicure. MarketBeat recorded 31 mentions for Alto Neuroscience and 0 mentions for Exicure. Alto Neuroscience's average media sentiment score of 0.11 beat Exicure's score of 0.00 indicating that Alto Neuroscience is being referred to more favorably in the news media. Company Overall Sentiment Exicure Neutral Alto Neuroscience Neutral Do analysts prefer XCUR or ANRO? Alto Neuroscience has a consensus price target of $8.50, indicating a potential upside of 121.07%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, analysts clearly believe Alto Neuroscience is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 Which has preferable valuation & earnings, XCUR or ANRO? Exicure has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K47.27-$9.70M-$3.88-0.96Alto NeuroscienceN/AN/A-$61.43M-$2.39-1.61 Do institutionals and insiders believe in XCUR or ANRO? 42.8% of Exicure shares are owned by institutional investors. 3.9% of Exicure shares are owned by insiders. Comparatively, 11.1% of Alto Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is XCUR or ANRO more profitable? Alto Neuroscience's return on equity of -44.34% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -192.16% -84.30% Alto Neuroscience N/A -44.34%-36.73% SummaryAlto Neuroscience beats Exicure on 9 of the 14 factors compared between the two stocks. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.64M$3.13B$5.77B$10.40BDividend YieldN/A2.37%5.74%4.63%P/E Ratio-0.9620.9177.0026.77Price / Sales47.27385.22497.21161.41Price / CashN/A45.3237.1760.63Price / Book3.349.7013.736.40Net Income-$9.70M-$53.02M$3.29B$271.62M7 Day Performance-3.61%1.22%1.07%2.89%1 Month Performance-42.28%7.94%6.35%9.66%1 Year Performance-4.83%10.40%81.07%31.48% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure0.8076 of 5 stars$3.74-3.6%N/A+69.4%$23.64M$500K-0.9650Gap UpANROAlto Neuroscience2.4857 of 5 stars$3.77-3.0%$8.50+125.2%-69.0%$102.20MN/A-1.58N/ATrending NewsSRZNSurrozen2.1407 of 5 stars$11.71+3.0%$38.50+228.9%+49.6%$100.31M$10.65M-0.8180Gap DownEXOZeXoZymes0.4661 of 5 stars$11.76-2.0%N/AN/A$98.67M$70K0.0029Gap DownCNTBConnect Biopharma3.8189 of 5 stars$1.74-3.3%$7.00+302.3%+38.8%$96.95M$26.03M0.00110IPAImmunoPrecise Antibodies2.3898 of 5 stars$2.10+8.5%$4.00+90.9%+217.4%$96.68M$17.59M-3.0880Gap UpSTTKShattuck Labs3.9206 of 5 stars$2.00+6.4%$4.00+100.0%-38.9%$95.80M$5.72M-1.65100Short Interest ↓KALAKALA BIO4.3322 of 5 stars$13.62-5.9%$17.25+26.7%+202.2%$95.47M$3.89M-2.0030News CoverageAnalyst ForecastAnalyst RevisionANIXAnixa Biosciences3.3464 of 5 stars$2.97-0.5%$9.00+203.5%-2.3%$95.47M$210K-7.805VIRIVirios TherapeuticsN/A$4.90flat$5.00+2.0%+2,350.0%$94.36MN/A-18.155ORMPOramed Pharmaceuticals0.3238 of 5 stars$2.29-0.7%N/A+0.8%$93.69M$1.34M-6.5310 Related Companies and Tools Related Companies Alto Neuroscience Alternatives Surrozen Alternatives eXoZymes Alternatives Connect Biopharma Alternatives ImmunoPrecise Antibodies Alternatives Shattuck Labs Alternatives KALA BIO Alternatives Anixa Biosciences Alternatives Virios Therapeutics Alternatives Oramed Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XCUR) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XCUR Stock Alerts